Floatz logo

MODERNA COVID-19 VACCINE RNA

AL Amyloidosis

Barbara Ann Karmanos Cancer InstitutevaccinePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the AL Amyloidosis cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
St. Olavs Hospital
Phase 3BB
Florbetaben
University of Zurich
Phase 3B
Cyclophosphamide
Alexion Pharmaceuticals, Inc.
Phase 3B
Selinexor
Washington University School of Medicine
Phase 2B
BIRTAMIMAB
Prothena Biosciences Ltd.
Phase 2B

View all 22 →

Same molecule, other indications

MODERNA COVID-19 VACCINE RNA is also rated in:

secondary progressive multiple sclerosisDormant
B
Indicative ·
62 / 100
View asset →
neoplasmDormant
CCC
Indicative ·
55 / 100
View asset →
multiple sclerosisDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →